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Abstract
The chapter focuses on understanding the latest classification of the pituitary
adenomas in light of immuno-histological and molecular signatures as envisaged in
the latest WHO classification guidelines. It further looks into evaluating and
analysing the symptoms of the adenoma locally and at distant organs. Imaging and
hormonal analysis has been discussed in detail for both functional, non-functional
and pituitary apoplexy. Further, the therapeutic options- medical, surgical and their
outcomes have been highlighted.
Keywords: Functional, non-functional, recurrent, approach, outcomes
1. Introduction
Pituitary adenoma (PA) is the third most common intracranial neoplasm
accounting for approximately 15% of all such tumors and is the commonest one,
accounting for 85% of sellar and suprasellar region. These tumors arise from various
cells in the pea sized gland, measuring about 0.5 gms, located in a bony cavity of the
sphenoid bone called sella turcica (Latin for Turkish seat) covered by dura all
around, cavernous sinuses laterally and its anterior and posterior intercavernous
venous channels [1–4].
2. Development and histology
Human pituitary gland is composed of two anatomically and functionally dis-
tinct parts: the adenohypophysis (anterior) and the neurohypophysis (posterior).
The adenohypophysis develops from an evagination of primitive stomatal ecto-
derm, Rathke’s pouch. The neurohypophysis originates from the infundibular pro-
cess of the diencephalon [5].
Adenohypophysis is an epithelial gland of endodermal origin and is composed of
acini that contain the six specialized hormone- secreting cells within a reticulin -rich
stroma. It is controlled by hypothalamic hormones that stimulate or inhibit the
release of anterior pituitary hormones. The posterior pituitary is composed of
axonal processes of neurons whose cell bodies are located in the supraoptic and
paraventricular nuclei of the hypothalamus, and pituicytes (modified glial cells).
Pituitary development is complex and includes a highly spatio-temporally regu-
lated network of integrating extrinsic signaling pathways and homeobox
1
transcriptional factors. Timely activation of signaling molecules is required for
evolution of pituitary gland and to determine cell-specific lineages for hormone
production [6].
The factors involved in early organogenesis and maintenance of pituitary pri-
mordium are six homeodomain proteins- (1) paired homeodomain proteins like
Prx 1 and Prx 2, (2) LIM homeodomain transcription proteins, (3) SOX transcrip-
tion factors (4) WNT/ beta-catenin and (5) Notch signaling. Transcriptional factors
which play main role in lineage determination, cytodifferentiation and hormonal
production, that target specific hormonal genes.
3. Pituitary specific transcription factors
Three main pathways have been described in cell differentiation in adenohy-
pophysis (Figure 1) and have become a part of tumour classification in the most
recent WHO 2017 classification [7–9]:
1.Pituitary transcription factor 1 (PIT1): has role in differentiation of
somatotroph, thyrotroph, lactotroph, mammosomatotrophs and their
respective tumours.
2.Steroidogenic factor 1 (SF1): is responsible for differentiation of gonadotrophs
and is expressed in gonadotrophic adenomas.
3.T-box pituitary transcription factor (TPIT): is responsible for transcription of
pro-opiomelanocortin, a precursor of adrenocorticotrophic hormone and is
expressed in corticotroph adenomas.
4. Ancillary IHC markers
1.Low molecular weight cytokeratin (LMWCK): are important in differentiating
sparsely vs. densely granulated tumours. In the former, >70% of tumour is
occupied with paranuclear cytokeratin positive fibrous body and less of
secretory granules.
Figure 1.
Factors involved in lineage specific adenohypophysial cells.
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2.Estrogen receptor alpha (ER): is expressed in lactotroph and gonadotroph
adenomas
3.GATA transcription factor 2 (GATA2): is expressed in gonadotroph and
thyrotroph adenomas.
5. Genes associated with pituitary adenomas
Few genes have been identified as causes of pituitary adenomas-
5.1 Familial pituitary tumor syndromes
1.Multiple endocrine neoplasia type 1 (MEN 1)- Mutations in the coding for
menin, reverses functions of tumor suppressor genes. Patients with MEN1
present with anterior pituitary adenomas in approximately 40% of all cases
and have been described in children as young as 5 years. Most of the PAs in
MEN1 are PRL-secreting (42–62%) or non-functioning tumors (15–42%), but
GH- (6.5–9%) and ACTH-secreting (3–4%) adenomas have also been
described. PAs in MEN1 have higher chance of co-secreting multiple hormones
compared to MEN1-negative patients, in up to 39% of cases. PAs in MEN1 are
considered more aggressive and at higher risk for resistance to treatment,
especially in children with large prolactinomas [10–12].
2.Multiple endocrine neoplasia Type 2 (MEN-2)- are caused by RET gene
mutations, which codes for a transmembrane receptor with tyrosine kinase
activity acting as a proto-oncogene [12–15].
3.Multiple endocrine neoplasia type 4 (MEN 4)- is caused by CDKN1B gene
mutations, which codes for a cyclin-dependent kinase (p27) that regulates cell
cycle and progression from G1 to S phase of mitosis. MEN4 is a rare genetic
syndrome, accounting for approximately 1.5–3% of patients clinically
classified as MEN1, without genetic defects in MEN1 gene [16–19].
4.Carney complex (CNC)- Carney complex (CNC) describes the constellation of
myxomas, spotty skin pigmentation, and endocrine overactivity due to
germline mutations of the PRKAR1A gene and are responsible for more than
70% of cases of CNC. PRKAR1A codes for the type 1 alpha regulatory subunit
of the protein kinase A (PKA) tetramer, inactivation of which leads to
dissociation of the regulatory from the catalytic subunit, aberrant activity of
PKA and phosphorylation of downstream targets, leading to cell proliferation
and tumour formation. Pituitary involvement in CNC is thought to be a
progressive disorder with normal pituitary tissue progressing to somato-
mammotroph hyperplasia and subsequently, to distinct tumour formation.
Thus, multiple adenomas may be present synchronous or metachronous in the
same patient [20–23].
5.Familial isolated pituitary adenomas (FIPA)- Familial pituitary tumors that are
not associated with MEN 1 and CNC have been united under a new term-
FIPA. It is used to describe families with at least two members with pituitary
adenomas, with or without other abnormalities. About 15–25% of patients
with FIPA harbour mutations in the AIP gene. This reaches up to 75% when




receptor- interacting protein, 11q13) acts as tumor suppressor gene and its
mutation predisposes to growth hormone secreting adenomas [24–27].
5.2 Sporadic pituitary adenomas
These account for 40% of GH adenomas and are due to mutations in Gs alpha
gene mutations which results in cAMP/PKA signal transduction pathway leading to
neoplastic transformation of somatotroph cells [28].
6. Pathology
All somatotrophic adenomas definitely express PIT-1 transcriptional factor and
GH hormone. These tumors are broadly classified into pure somatotroph adenoma
and Mixed somatotroph adenoma with co-expressing PRL or other hormonal
markers. Based on secretary granules of GH, Pure somatotroph adenomas are fur-
ther divided into two clinically significant and morphologically distinct subtypes:
sparsely granulated (SG) and densely granulated (DG) somatotroph adenomas.
Mixed SA are further classified into Mammosomatotroph adenomas (MSA), mixed
somatotroph-lactotroph adenomas (MSLA) and plurihormonal adenomas.
Similar to other adenomas, SA are soft white to grey macroscopically. MSA are
smaller in size with better prognosis compared to MSLA are larger with more
invasiveness at the time of presentation.(75) SA are often seen arising from GH
expressing pituitary cells in lateral wing of the gland. Extra seller extension of these
tumors gives a characteristic shape of snowman (76).
Microscopically, SA share characteristics of other endocrine tumors: colonies of
relatively large monomorphic cells with eosinophilic cytoplasm and spherical
nuclei. Disruption of dense reticulin meshwork around the nests of cells distin-
guishes PA from normal pituitary cells (Figure 2). Hyperplasia to adenoma pro-
gression of SA were observed in some cases with familial isolated pituitary adenoma
and X-linked acro-gigantism syndrome. (112) DGSAs are the most common and
expresses diffuse cytosolic positively of GH and cytokeratin (CAM 5.2). These are
predominantly seen in older age group with slower growth and excellent response
to somatostatin treatment. SGSA are less common and behave differently with more
aggressive nature like being larger, more invasiveness & proliferation and poor
response to somatostatin response. They show co-segregation of cytokeratin and
growth hormone granules resulting in characteristic fibrous bodies. These bodies
Figure 2.
Histopathological section of pituitary adenoma exhibit colonies of monomorphic round cells with disruption of
reticulin meshwork. (H & E 100X, (insert- Reticulin stain) and 200X).
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are juxtanuclear keratin aggregates highlighted by cytokeratin immunohistochemi-
cal stain (CAM 5.2). MSA are histologically similar to DGSA and ultra-structurally
distinct a single cell expressing both GH and PRL granules. MSLA are composed of
mixture of two different cells with GH and PRL secreting granules respectively.
Either of the cell population can be densely or sparsely granulated with various
combinations.
7. Radiology of pituitary tumors
‘The Pituitary Body and its Disorders’ was one of the first books written on the
subject of Neuroradiology, based on work done at the Johns Hopkins Hospital, and
consisted of detailed explanation of lesions detected on radiographs [29].
Pituitary imaging is indicated in patients, presenting with symptoms secondary
to derailed pituitary hormones or symptoms indicating pituitary mass, like visual
field deficit or headaches.
The sella turcica, as described earlier in chapter, is located deep within the
cranium and can be demonstrated on a number of projections of skull radiographs.
A right or left true lateral view of the skull demonstrates a clear profile view of sella
and dorsum sellae. In a properly positioned lateral skull supine view, the line
extending from the outer canthus of the eye to the external auditory meatus is
perpendicular to the table. A caudally angled occipito-frontal projection, or Skull PA
Axial (Caldwell View) is taken to demonstrate the floor of sella turcica. In this view,
X-rays pass at an angle of 15 degrees from occiput and exit at the nasion, with film
kept perpendicular to the orbitomeatal line (OML). For demonstration of dorsum
sellae through the foramen magnum, Haas View, another Skull PA Axial view is
taken where the central ray is angled 25 degrees cephalad to the orbitomeatal line
(OML). The patient sits or stands facing an upright Bucky with the forehead and
nose touching the imaging receptor. The neck is flexed to bring the OML perpen-
dicular to the IR. It has been proven that PA axial radiographs add wealth of
information pertaining to sella, and is complimentary to the sagittal view [30, 31].
Radiographic signs associated with pathology of pituitary gland and surrounding
structures include i) enlargement with associated distortion of shape of the sella
turcica, usually associated with empty sella syndrome or pituitary tumors, ii) Ero-
sions in the floor or lateral walls, secondary to aneurysms or chronic increased
intracranial pressure, iii) Sclerosis of the tuberculum or clinoid processes due to
meningioma involving diaphragm sellae, iv) Sclerosis of sellar floor likely secondary
to nasopharyngeal carcinoma or craniopharyngioma, v)Fat or calcifications in the
intrasellar, suprasellar or parasellar region indicate presence of germ cell tumors or
craniopharyngioma, vi) Eggshell calcification may point towards presence of aneu-
rysms, Rathke’s cyst or craniopharyngioma [32–34]. Usually sellar to cranial index
of more than 8 is considered as abnormal and indicative of a sellar lesion on lateral
skull radiograph [35].
With advent of Computed Tomography (CT) and Magnetic Resonance Imaging
(MRI), MRI has become the modality of choice for imaging of pituitary lesions, due
to its better soft-tissue contrast details and its ability to demonstrate pituitary gland
and parasellar anatomy with increased spatial resolution and without artefacts from
surrounding bones. CT is usually reserved for patients with contraindications to
MRI and for those undergoing emergent evaluation.
In normal adults, the anterior pituitary is isointense to grey matter on T1-
weighted and T2- weighted sequences, while posterior pituitary is inherently
hyperintense onT1 weighted sequences, appearing as bright spot, secondary to




pituitary. In neonates till 2 months of age and in pregnant women, the anterior
pituitary may be as hyperintense as the posterior pituitary. On post contrast
dynamic imaging, the enhancement of infundibulum is seen earlier than posterior
pituitary, which turn enhances earlier than anterior pituitary [36].
Radiologically, pituitary adenomas are classified by size; microadenomas are 10mm
or less in diameter, and macroadenomas are greater than 10 mm in diameter.
Microadenomas usually show signs and symptoms of hormonal excess, and if
suspected, previous biochemical analysis for pituitary hormones is helpful in indicating
a dynamic pituitary scan for their diagnosis. They could be either, prolactinomas,
growth hormone-secreting adenomas or ACTH-secreting tumours. OnMRI,
microadenomas are iso to hypointense on T1W images and usually appear hyperintense
on T2W sequences. Dynamic imaging following bolus injection of contrast, is helpful in
depicting differential uptake of contrast between amicroadenoma and normal pituitary
gland and thus increases the detection rate of microadenomas [37, 38].
Pituitary macroadenomas are twice as common as microadenomas and are the
most common suprasellar masses, resulting in visual symptoms. A slow-growing
macroadenoma expands the bony sella and extends into the suprasellar cistern,
giving “figure of 8” or “snowman” like appearance because the rigid diaphragm
sellae. On CT imaging, macroadenomas are isodense to the surrounding brain,
however, scalloping/destruction of the surrounding bones is better depicted on CT.
On MRI, macroadenoma appears isointense to gray matter on T1- and T2-weighted
MR images, and usually demonstrates intense contrast enhancement unless there
are areas of necrotic degeneration or hemorrhagic foci within [39].
Invasive macroadenomas are usually prolactin-excreting tumors, and in such
cases prolactin levels found are more than 1000 ng/dL [40]. It is difficult to distin-
guish invasive adenomas from rarer pituitary carcinoma, only on imaging.
Microadenomas may occasionally present with intrapituitary hemorrhage or
tumor cyst without discerning solid component on MRI. Such cystic lesions within
microadenomas are usually off midline unlike Rathke’s cleft cyst, and are sometimes
difficult to differentiate. In such cases, temporal growth of the lesion or associated
hormonal changes give an indication of tumoral lesion. Intralesional hemorrhage
can be picked up as hyperdense focus on CT and show peculiar MRI signal on T1W
and T2W sequences based on the age of bleed.
Non adenomatous tumors of pituitary like, pituicytoma, spindle cell oncocytoma
or granular cell tumors, are usually suprasellar/infudibular in location and some of
them like granular cell tumors appear hyperdense on CT. Pituicytomas show
homogeneous vascular enhancement on post contrast studies and are more vascular
than adenomas, and their posterior location and increased vascularity makes them
amenable for complete resection [41].
8. Classifications
Pituitary adenomas are broadly classified as functioning or non-functioning
adenomas based on hypersecretion of specific hormones [42–47].
Functioning adenoma account for 2/3 of pituitary adenomas and present with
specific clinical sign and symptoms related to excess hormonal secretion. Non-
functioning adenomas account for 1/3 of all pituitary tumors, where they present
incidentally or with clinical signs and symptoms related to degree of mass effect on
adjacent structures with no evidence of hormone excess either clinically or on
biochemical analysis. These are considered to be producing inactive peptides/gly-
coproteins or the hormone secretion was defective. These are further subtyped
as-silent adenomas and null cell adenomas.
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The definitions and thus the incidence of such adenomas has seen a sea of
change with the addition of transcription factors and other IHC markers. Null cell
adenomas are defined as non-functional adenomas that are immune-negative for all
hormones and pituitary specific transcription factors and has led to decrease of their
incidence from 16.5% to <1% and has also led to the emergence of silent
gonadotroph adenomas which were underdiagnosed. Silent adenomas were earlier
described on ultrastructural findings on electron microscopy are now defined as
tumors with no clinical or biochemical features of hormone excess but are positive
for pituitary specific transcription factors. Silent corticotroph adenoma was classi-
cally described and subtyped as- I) densely granulated, II) sparsely granulated and
III) Subtype 3. The immunoreactivity with PIT1 and inconsistent immunoreactivity
to POMC has led to dropping of the word “corticotroph” from subtype 3and has
been classified along with plurihormonal PIT1 adenomas (Table 1).
The new WHO classification of tumors of pituitary was mainly based on mor-
phology and function of tumor cells (Table 2). Diagnostic and prognostic practical
aspects included in new WHO are summarized below:
1.Elimination of term ‘Atypical Adenoma’: This term atypical adenoma was used
for invasive tumors with invasiveness with elevated Ki67/MIB-1 and > 3%
immunostaining for p53. This has been replaced by “high risk adenomas” and
Includes
a. Sparsely granulated somatotroph adenoma
b. Lactotroph adenoma in men
c. Crooke’s cell adenoma
d. Silent corticotroph adenoma
e. Plurihormonal PIT1 positive adenoma.
2.Deletion of the term Oncocytoma, which is now considered a subset of
gonadotroph adenoma.
3.A novel approach for classifying pituitary neuroendocrine tumors according to
pituitary adenohypophyseal cell lineage pituitary specific transcription factors.
4.Re-definition of old entities like the null-cell adenoma based on pituitary
specific transcription factors.
5. Introduction of new entities like pituitary blastoma, associated with DICER1
mutations, occurring exclusively in infants and children younger than 24months.
Transcription factors IHC Diagnosis
SF1 + FSH+/LH+/ER+ Gonadotroph
SF1 + FSH-/LH/ER- Gonadotroph
TPIT1+ ACTH- Silent corticotroph
TPIT 1+ ACTH + Silent corticotroph
PIT 1+ Variable GH/Prl/TSH/ER Pit-1 lineage, poorly differentiated











Densely granulated somatotroph adenoma GH  PRL  α-subunit PIT-1 Perinuclear or diffuse
positivity
Sparsely granulated somatotroph adenoma GH  PRL PIT-1 Dot-like (fibrous body) Aggressive
Mammosomatotroph adenoma GH  PRL  α-subunit PIT-1, ER-∝ —





Densely granulated lactotroph adenoma PRL PIT-1, ER-∝ —
Sparsely granulated lactotroph adenoma PRL PIT-1, ER-∝ —
Acidophil stem cell adenoma PRL  GH, PIT-1, ER-∝ Dot-like (fibrous body) Aggressive




b-TSH, α-subunit PIT-1, GATA2 —
4 Corticotroph
adenoid
Densely granulated ACTH, T-PIT Diffuse
Sparsely granulated ACTH, T-PIT Diffuse
Crooke’s cell adenoma ACTH, T-PIT Ring-like Aggressive




b-FSH, b-LH, α-subunit SF-1, GATA2, ER-∝ —
6 Null cell adenoid No markers None —
7 Plurihormonal
adenoid
Plurihormonal PIT-1 positive adenoma
(previously called subtype 3 adenoma)
GH, PRL, b-TSH,  α-subunit PIT-1 — Aggressive














6.Introduction of new entities like plurihormonal tumors based on
immunohistochemical combinations.
7.Introduction of double/multiple adenomas that show geographically distinct
cell populations.
8.Replacing terminologies like term “hormone producing” has been changed to
‘troph’ to emphasize the role of transcription factors in cell differentiation and
specific regulatory hormones of adenohypophysis.
Significant changes affecting the diagnosis of pituitary adenomas (PA) were
introduced, and simultaneously panels of experts have also proposed replacing the
term PA for Pituitary neuroendocrine tumour (Pit NET) [42–47].
9. Non-functioning pituitary adenomas
Non-functioning pituitary adenomas (NFPAs) are benign pituitary neoplasms
that arise from the adenohypophyseal cells and lack clinical or biochemical evidence
of hormone excess except for a mild hyperprolactinaemia in some cases, due to stalk
effect. They account for 14–54% of pituitary adenomas. These include the silent
adenomas and the null cell adenomas. Oncocytomas, which were included as a
subset of null cell adenomas are now an obsolete term, and are accepted as pheno-
type with abundant mitochondria.
Immunohistochemical, secretory studies, in vitro tissue cultures have demon-
strated the presence of all adenohypophyseal hormone components in the adeno-
mas, the most common being the gonadotrophs. Even electron microscopic studies
have shown that these tumour cells have secretory granules despite having
assayable hormones. Chromophobe adenomas have also shown staining for ACTH
despite being clinically negative for Cushing’s syndrome or elevated cortisol levels.
9.1 What makes these tumors non-functional?
Various explanations have been offered to these tumours which have positive
transcription factors except null cell adenomas for being hormonally or clinically
negative. These are-
1.The glycoprotein hormones like FSH, LH, TSH need a combination of both
alpha and beta subunits and these tumours might be producing the
uncombined subunits and hence are clinically inactive.
2.Low levels of hormone production resulting in near normal values.
3.Abnormalities is secretion despite normal synthesis.
4.Lack of specific assays for subunit detection [48–52].
9.2 Clinical presentation
The clinical spectrum of NFPA varies from being completely asymptomatic to
causing significant hypothalamic/ pituitary dysfunction and visual field compro-
mise due to their large size. The absence of clinical symptoms of hormonal




1.96  2.9 years. Most patients present with symptoms of mass effect, such as
headaches, visual field defects, ophthalmoplegias, and hypopituitarism. Other
manifestations are hyperprolactinaemia due to pituitary stalk deviation and less
frequently pituitary apoplexy (3.7–14.1%) [53, 54].
Headaches have been described with a varying incidence of 19–75% regardless of
the size of the tumours. The possible reasons for the headaches are- (a) increased
intrasellar pressure and stretching of dural membranes containing pain receptors,
(b) activation of trigeminal pain pathways by tumours affecting the cavernous
sinus (c) due to apoplexy, or (d) hydrocephalus [55].
Neuroophthalmological symptoms are caused by the pressure effects, ischemia
or a combination of both on the on the optic chiasm. The typical visual field defect
associated with pituitary tumours is bitemporal hemianopia, occurring when the
body of the chiasm (which is comprised of the crossing nasal fibres of each optic
nerve) is compressed by the enlarged gland. Variations in the anatomy of the
chiasm leads to different patterns of field loss which can be uni-, bilateral or even
central. The defect may be complete, involving the whole hemi-field or partial,
usually beginning superiorly and progressing inferiorly, depending on the degree of
nerve compression. Macular fibres, located in the postero-superior quadrant are
more distant and are late to be involved. Chronic compression may lead to primary
optic atrophy and may lead to decrease in the visual acuity.
Ophthalmoplegia is caused by pressure on the abducens or oculomotor nerves in
the cavernous sinus. The invasion of the cavernous sinus (parasellar expansion)
may affect the cranial nerves, causing a varied clinical profile according to the
compromised nerve: ptosis (III nerve lesion), deviation of the eyeball superiorly and
slightly inward (IV nerve involvement) and convergent strabismus (lesion VI
nerve) [56].
Giant tumours, defined as ≥40 mm in one dimension or within 6 mm of Fora-
men of Monro, may rarely cause obstructive hydrocephalus. Erosion of the sellar
floor may lead to CSF rhinorrhoea [57–59].
NFPAs may demonstrate mild elevations in serum prolactin (“disconnection
hyperprolactinaemia”), due to blockage of dopamine which inhibits the lactotrophs.
However, this value is never beyond 2000 mU/L. Mechanical compression of the
normal anterior pituitary gland and/or pituitary stalk may prevent the passage of
stimulatory hypothalamic factors resulting partial or complete hypopituitarism.
Hypopituitarism develops slowly and often goes undetected. The overall prevalence
of partial hypopituitarism in patients with NFPAs ranges from 37 to 85%.
Panhypopituitarism occurs in 6–29% of patients and GH axis is affected in 61–100%
of patients showing laboratory evidence of GH deficiency [60–62].
Central hypogonadism is noted in 36–96% of patients and adrenal insufficiency
is noted in 17–62%. Finally, 8–81% exhibit central hypothyroidism. Presentation
with diabetes insipidus is very rare [63].
9.3 Investigations
The investigations are aimed at-
1.Detecting the hormonal deficiencies,
2.Find out any hormonal excess especially double dilution to rule out Hook
effect in hyperprolactinemia.
3. Imaging, the preferred one is MRI brain to demonstrate the morphology of the
tumor, invasion of surrounding structures and assess the targeting routes.
10
CNS Malignancies
4.Neuro-opthmological evaluation includes visual acuity, field vision and fundus
characterisation.
The differential diagnosis of an incidentally discovered sellar mass is broad and
includes a large number of entities: anterior pituitary tumours, posterior pituitary
tumours (e.g., pituicytoma, granular cell tumours), benign parasellar tumours (e.g.,
meningioma, craniopharyngioma), malignant tumours (e.g., glioma, germ cell
tumour), developmental lesions (e.g.,, Rathke’s cleft cysts, dermoid cyst,
epidermoid cyst, arachnoid cyst), inflammatory and granulomatous lesions (e.g.,
lymphocytic hypophysitis, granulomatous hypophysitis, Langerhans cell
histiocytosis) and vascular lesions (e.g., aneurysms) [62].
9.4 Grading of tumor
1.Based on the size of tumor
a. Microadenomas- less than 10 mm
b. Macroadenomas- 10 mm to 40 mm in size
c. Giant pituitary adenomas- tumors in excess of 40 mm in size, or extending
within 6 mm of Foramen of Monro
2.Hardy’s Classification [64–66]
The large variation in sellar invasion and suprasellar extension of pituitary
adenomas was recognized in the 1970s by Hardy and Vezina and prompted the
development of the Hardy classification criteria to better characterize these
lesions. Since that time, the Hardy classification system has served as a
descriptive tool for pituitary adenomas and is often utilized in research studies.
The Hardy classification comprises of two subscales: one describes the integrity
of the sellar floor and invasion into the sphenoid sinus (Grades 0–IV), whereas
the other describes the degree of suprasellar extension of the tumor (Types A–
D). Although these two subscales were described using lateral radiographs and
encephalograms, respectively, the Hardy grading scale is still used to classify
adenomas based on magnetic resonance imaging (MRI) scans.
Sellar Invasion
Grade 0 The enclosed adenoma is described as a tumor that remains within the anatomical
confines of the osteo-aponeural sheath of the sella turcica. The floor of the sella is
always intact.
1 The sella turcica is within normal limits in size (less than 16  13mm; 208 mm) but
shows a lowering of the floor on one side or a bulging of the cortex.
2 The sella turcica is enlarged to various degrees but the floor remains intact.
3 The sella is more or less enlarged but there is a local erosion or destruction of the floor.
4 The entire floor of the sella is diffusely eroded or destroyed, giving a characteristic
“phantom sella” with all the boundaries barely visible.
Suprasellar
extension
Type O The tumour is entirely confined within the sella turcica.
A The suprasellar expansion bulges into the chiasmatic cistern but does not reach the




B The tumour reaches the floor of the third ventricle, giving the image of an inverse
cupula of the anterior recesses of the third ventricle.
C A voluminous suprasellar expansion bulges largely into the third ventricle up to the
foramen of Monro.
D Rare aberrant expansions occur in temporal or frontal fossa.
3.Wilson’s modification of Hardy’s classification [67]
Wilson modified Hardy’s classification to distinguish between extrasellar
extensions, including extension into the cavernous sinus.
Suprasellar extension
0: none
A: expanding into suprasellar cistern
B: anterior recesses of 3rd ventricle obliterated
C: floor of 3rd ventricle grossly displaced
Parasellar extension
D: intracranial (intradural); specify (1) anterior (2) middle, or (3) posterior
fossa
E: into or beneath cavernous sinus (extradural)
Invasion
Floor of sella intact
I: sella normal or focally expanded; tumor <= 10 mm
II: sella enlarged; tumor > = 10 mm
Sphenoid extension
III: localized perforation of sellar floo
IV: diffuse destruction of sellar floor
Distant spread
V: spread via CSF or blood-borne
4.Knosp’s grading for invasiveness into cavernous sinus
Knosp et al. introduced a classification of the parasellar extension of PAs based on
MRI coronal sections. Three lines (medial, median and lateral), which cross the
internal carotid artery (ICA), determine the degree of invasion. They further
suggested a subdivision of grade 3 into 3A and 3B: in Grade 3A, the tumor extends
laterally in the superior compartment of the cavernous sinus, whereas in Grade 3B
the lesion extends laterally, but in the inferior compartment. This finding is
clinically and biologically relevant, and is most probably the consequence of better
surgical visualization provided by an endoscope [68–70].
Grade 0 No involvement of the cavernous sinus (normal condition)
1 The tumour pushes into the medial wall of the cavernous sinus, but does not go beyond a
hypothetical line extending between the centres of the two segments of the internal carotid
artery (non-invasive PA)
2 The tumour goes beyond hypothetical line, but without passing a line tangent to the lateral
margins of the artery itself (non-invasive PA)
12
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3 The tumour extends laterally to the internal carotid artery within the cavernous sinus
(invasive PA)
4 Total encasement of the intra-cavernous carotid artery (invasive PA)
9.5 Treatment
The primary goal of treatment of these non-functioning adenomas is reduction
of the tumour mass and relieve the compressive effects on the optic apparatus,
ventricular system, cavernous sinus and adjacent brain parenchyma.
In the absence of visual impairment, the optimal treatment choice is still a
matter of debate, especially in patients presenting with hypopituitarism, headache,
or tumours close to the chiasma. Surgery may improve pituitary function in up to
30% of patients with pre-existing hypopituitarism, but the risk of new hormone
deficiency following surgery is 2–15%. Therefore, hypopituitarism alone is not an
indication for surgical treatment. Surgical resection of non-functioning
microadenomas is not indicated since tumour growth is rare (3–13%) with less than
5% growing > 1 cm during long-term follow-up.
Surgical excision either through trans-sphenoidal endoscopic or microscopic or
trans-cranial route are the mainstay.
Bromocriptine, Octreotide and other agents have been shown to be partially
successful in reducing the tumour.
Radiotherapy is indicated in case of inadequate tumour resection, high mitotic
index and at recurrence.
Gross total resection is achieved in 60–73% of patients with NFPAs. In a recent
meta-analysis on NFPA patients, TSS was associated with 1% mortality. Postopera-
tive complications such as cerebrospinal fluid (CSF) leakage, fistula, meningitis,
vascular injury, persistent DI, or new visual field defect occurred in ≤ 5% of
patients. Surgical complications are reported to be less frequent with higher-volume
surgeons or hospitals. The risk of CSF leakage is increased in patients with large
adenomas with suprasellar extension, intraoperative CSF leakage, repeat TSS, and
high body mass index.
9.6 Outcomes
The visual improvement in acuity and visual fields is seen in 70–80% following
gross total or subtotal excision of tumours [71–73].
9.7 Residual or recurrent NFPA
The rate of complete excision of these nonfunctional adenoma varies from 60 to
70% depending on the experience of surgeon. Additional use of intra-operative MRI
has increased the rate of complete removal to 82%. Factors leading to less than
complete removal are- 1) invasion into cavernous sinus, 2) increased diameter, and
3) absence of apoplexy [74].
Recurrences following complete removal of tumour is usually low. Recurrence
rates in 10-year follow-up was found to be approximately 5%, 25% and 50% for
initial complete removal, suspicious residue and initial incomplete removal,
respectively.
Indications for re-surgery for both recurrences or growing remnants are- 1)





Management of recurrence is based on the following factors- 1) time of tumour
recurrence, 2) size and location, 3) age, 4) general condition, 5) ophthalmological
findings, 6) neurological findings and 7) endocrine findings.
Re-do surgery is recommended for accessible tumours in young and healthy
adults. Early recurrences after complete excision are better treated with radiother-
apy. Small and asymptomatic recurrences need to be followed up for tumour
growth and clinical factors. Elderly with severe systemic diseases is managed con-
servatively [75–86].
10. Lactotroph adenomas or prolactinomas
LA are also derived from PIT-1 lineage adenohypophyseal cells with chief
expression of PRL. LA are the most common hormone expressing pituitary ade-
noma, accounting for 30–50% of all adenomas. The reported prevalence is 35 per
100,000 people. The highest incidence is seen in women of child-bearing age and in
patients with MEN 1 [87–90].
10.1 Clinical presentation
This endocrinopathy which was classically described as amenorrhea-
galactorrhea syndrome was first described to be associated with prolactin
hypersecretion by Forbes in 1954. However, the manifestations are quite varied
among the genders and in females in relation to their menopausal status. The
increased levels of prolactin cause decrease in the levels of gonadotropins resulting
in hypogonadism. In females in reproductive ages, they present with- 1) delayed
puberty, 2) oligomenorrhea, 3) primary or secondary amenorrhea or 4) regular
menstural cycles with infertility. Galactorrhea is seen in 30–80% females in this age
group. Post-menopausal women and men, who conspicuously lack these features,
present with visual disturbances and subtle symptoms like loss of libido or
dyspareunia. Osteoporosis which was earlier considered due to direct effects of
prolactin on the bone is correlated to hypogonadism and lack of estrogen in women.
Headaches are a common presentation in all. Psychiatric manifestations include
hostility, depression, anxiety and weight gain [90–92].
10.2 Pathology
Macroscopically, LA are pseudo capsulated and show grey white appearance
with firm consistency and gritty on cut. Stromal amyloid deposition and microcal-
cification are observed in few cases. Some tumors have microscopic invasion and
some macroadenoma are widely invasive into adjacent structures. SGLA are distinct
from DGLA, as the prolactin staining pattern is paranuclear golgi type. ASLA are
composed of abundant vacuolated eosinophilic cytoplasm, so called oncocytic
change and occasional fibrous bodies.
Immunohistologically, these tumors are subdivided into sparsely granulated
lactotroph adenoma (SGLA), densely granulated lactotroph adenoma and acidophil
stem cell adenoma (ASCA). These subtypes have a distinct biological behavior and
response to treatment. LA are most common in women and predominantly seen in
childhood and adolescents age group. Biological and prognostically distinct differ-
ences are observed between males and females. In men, tumor present more
aggressively with invasiveness and 80% are larger of them are macroadenoma,
whilst size of tumor is small in women. Estrogen plays a significant role in
14
CNS Malignancies
pathogenesis of tumor. A significant correlation between the estrogen receptor and
tumor volume was observed, but mechanism is not known.
10.3 Laboratory evaluation
The normal levels of prolactin are <20 ng/ml. Single elevation of >200 ng/ml
are almost always due to prolactinomas. However, the values between 20 and
200 ng/ml need careful evaluation of drug, systemic condition and correlation with
the size of the tumour to rule out “pseudo-prolactinomas” due to “stalk sectioning
effects” [93].
Prolactin may be elevated in other conditions as well. Hence, a careful history
especially pertaining to drugs needs to be taken (Table 3). Non–prolactin-
producing macroadenomas can cause prolactin elevations from disinhibition of
prolactin secretion by compressing the pituitary stalk or hypothalamus. Very high
prolactin levels seen in macroadenomas can saturate the antibodies in the assays and
lead to artifactually low or normal results (the “Hook effect”) and prolactin levels
should be rerun at 1:100 dilution to exclude this possibility [8].
Two distinct biological profiles of prolactinomas have been observed- 1) benign
microadenomas with very little growth potential and 2) aggressive, invasive
macroadenomas. Natural history and autopsy studies have shown that not all





































microadenomas to macroadenomas is 3–7%. However, the natural history of
macroprolactinomas is not known. The risk of macroadenomas enlarging during
pregnancy is approximately 15%.
Dopamine agonist therapy is the mainstay of treatment, instituted to lower
prolactin levels, decrease tumour size, and restore gonadal function for patients
harbouring symptomatic prolactin-secreting microadenomas or macroadenomas.
Bromocriptine, the prototype dopamine agonist was introduced into clinical tri-
als in 1971. It acts by stimulating dopamine receptors on lactotrophs, a potent
analogue of dopamine, decreases cAMP activity, reduction in intracellular calcium,
and hence decreased synthesis and release of prolactin. It is given in doses of
5-20 mg/day in three divided doses. The cellular and ultra-structural changes
noticed after bromocriptine therapy are- 1) loss of cytoplasmic volume, 2) involu-
tion of rough endoplasmic reticulum, 3) at subcellular level, decrease in prolactin
gene transcription and translation, 4) in vivo PET studies demonstrating reduced
metabolic activity and 5) varying degrees of calcification, amyloid deposition,
perivascular and interstitial fibrosis. All the above except 5, are reversible especially
in macroadenoma. The fibrosis may preclude successful tumour excision. Bromo-
criptine resistance may be noted in 25% patients, 80% of whom may show response
to cabergoline [94, 95].
The long-acting dopamine agonist cabergoline is preferred due to its higher
efficacy in normalizing prolactin levels and pituitary adenoma shrinkage [8].
The higher efficacy is probably due to the higher affinity for dopamine receptor
binding sites. Control of hyperprolactinemia requires doses of cabergoline ranging
from 0.25 to 3 mg/wk.; resistance to cabergoline may be seen in upto 10% patients
and may require doses up to 11 mg/wk. [12, 13]. Echocardiograms should be advised
yearly in those patients exceeding a weekly dose of 2 mg, to look for valvular
regurgitation [96].
Another adverse effect of dopamine agonist, occurring in about 5% of patients,
is compulsive behaviour, such as excessive gambling and hypersexuality. Asymp-
tomatic patients harbouring a microprolactinoma may be followed up without
treatment. In patients with amenorrhea due to the microadenoma, the clinician can
choose between a dopamine agonist or oral contraceptives.
Resistance to therapy is defined by failure to achieve a normal prolactin level
and failure to achieve a 50% tumour reduction after maximal conventional doses of
DA (Bromocriptine >15 mgs per day or 2 mg/week of cabergoline for at least
3 months). The possible reason for resistance is decreased D2 receptor expression or
mutations in post receptor mechanisms.
The alkylating agent, Temozolamide, has been used in patients with malignant
prolactinomas.
Patients on medical management should be followed up at regular intervals in
the following manner:
a. Serum prolactin levels to be measured at regular intervals, beginning 1 month
after the start of treatment in order to guide the clinician for titration of
dopamine agonist therapy to achieve normo-prolactinemia/restore eugonadal
status.
b. Repeat MRI in 1 yr.
c. Earlier repeat MRI (in 3 months) in patients with macroprolactinoma, if
prolactin levels continue to rise while patient is receiving dopaminergic
agents, or in the presence of new symptoms, e.g., galactorrhoea, visual
disturbances, headaches, or other hormonal disorders.
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d. Visual field examinations in patients with macroadenomas at risk of
impinging the optic chiasm
e. Evaluation and management of comorbidities, e.g., sex steroid-dependent
bone loss, persistent galactorrhoea and pituitary trophic hormone reserve.
10.4 Surgical Indications for prolactinomas
1.Pituitary Apoplexy
2.Visual deficits due to compression of the optic apparatus
3.Cystic prolactinomas




8.Increasing tumor during pregnancy
9.Macroadenoma in psychiatric patients
Remission rates after surgical excision vary from 30 to 93%. Restarting DA
following surgical decompression normalises prolactin levels which can be
maintained at lower doses [97–101].
10.5 Surgical issues with pregnancy in prolactinomas
The major issue with regards to pregnancy in patients with prolactinomas are
1.Infertility
2.Risk of tumour growth during pregnancy
3.Effects on foetal growth
The risk tumour enlargement is upto 5% for microadenomas while it reaches
upto 15% for macroadenomas. However, prior surgery and/or radiotherapy
reduces this risk to 4.3%. Both surgery and bromocriptine therapy are equally
effective in microadenomas for fertility. However, no such comparison is
available for macroadenomas. Bromocriptine needs to be stopped at the first
sign of pregnancy [100, 102].
11. Somatotroph adenoma
Somatotroph adenoma (SA) is a subtype of pituitary adenoma which are derived
from PIT-1 lineage cells with GH expression and with or without co-expression of
prolactin (PRL). These tumors account for 10–15% of all pituitary adenoma, and





All somatotrophic adenomas definitely express PIT-1 transcriptional factor and
GH hormone. These tumors are broadly classified into pure somatotroph adenoma
and Mixed somatotroph adenoma with co-expressing PRL or other hormonal
markers. Based on secretary granules of GH, Pure somatotroph adenomas are fur-
ther divided into two clinically significant and morphologically distinct subtypes:
sparsely granulated (SG) and densely granulated (DG) somatotroph adenomas.
Mixed SA are further classified into Mammosomatotroph adenomas (MSA), mixed
somatotroph-lactotroph adenomas (MSLA) and plurihormonal adenomas.
Similar to other adenomas, SA are soft white to grey macroscopically. MSA are
smaller in size with better prognosis compared to MSLA are larger with more
invasiveness at the time of presentation.SA are often seen arising from GH
expressing pituitary cells in lateral wing of the gland. Extra seller extension of these
tumors gives a characteristic shape of snowman.
Microscopically, SA share characteristics of other endocrine tumors: colonies of
relatively large monomorphic cells with eosinophilic cytoplasm and spherical
nuclei. Disruption of dense reticulin meshwork around the nests of cells distin-
guishes PA from normal pituitary cells. Hyperplasia to adenoma progression of SA
were observed in some cases with familial isolated pituitary adenoma and X-linked
acrogigantism syndrome. (WHO 2017) DGSAs are the most common and expresses
diffuse cytosolic positively of GH and cytokeratin (CAM 5.2). These are predomi-
nantly seen in older age group with slower growth and excellent response to
somatostatin treatment. SGSA are less common and behave differently with more
aggressive nature like being larger, more invasiveness & proliferation and poor
response to somatostatin response. They show co-segregation of cytokeratin and
growth hormone granules resulting in characteristic fibrous bodies. These bodies
are juxtanuclear keratin aggregates highlighted by cytokeratin immunohistochemi-
cal stain (CAM 5.2). MSA are histologically similar to DGSA and ultrastructurally
distinct a single cell expressing both GH and PRL granules. MSLA are composed of
mixture of two different cells with GH and PRL secreting granules respectively.
Either of the cell population can be densely or sparsely granulated with various
combinations.
11.2 Clinical manifestations
Growth hormone adenomas are commonly seen in 4th and 5th decades with no
gender predominance. More than 60% are macroadenomas compared to other hor-
monally active tumors and hence have predominant local effects apart from systemic
effects. Endocrine systemic effects produce gigantism (pre-pubertal) and acromegaly
(after apophyseal fusion). Despite widespread changes including in the appearance,
the mean interval between the disease onset and diagnosis is 8.7 years [103].
The facial features described as “beetle brow” appearance include the following
changes- deeply furrowed scalp, coarse skin, frontal bossing, fleshy nose, promi-
nent nasolabial folds, thick lips, prognathism, maxillary widening, dental maloc-
clusion with increased inter-dental space and macroglossia with tooth marks on the
tongue. The voice changes include low pitched deep voice due to laryngeal hyper-
trophy and enlarged paranasal sinuses. Hypertrophy of sebaceous glands gives oily
appearance to the face. Enlargement of sweat glands gives rise to malodors.
[104, 105] Sleep apnea syndrome is seen in up to 75% of acromegalics [106–108].
Enlargement of hands which are thick, fleshy and are classically described as
“spade like hands”. The bony hyperostosis and soft tissue thickening causes
entrapment neuropathy like carpel tunnel syndrome.
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Periosteal new bone formation leads to osteophyte formation, disc degeneration
and spinal stenosis. Arthropathy of weight bearing joints is common. Myopathy is a
common feature of acromegaly.
Pachydermoperiostosis is a very rare osteoarthrodermopathic disorder whose
clinical and radiographic presentations may mimic those of acromegaly and should
be considered as a differential diagnosis [109].
The cardiovascular manifestations include hypertension, concentric
biventricular hypertrophy and arrhythmias. These changes in the cardiovascular
system are least resistant to reversal [110, 111].
Hypertrophy of internal organs like hepatomegaly and splenomegaly is fre-
quently encountered. Diabetes mellitus and islet cell neoplasms are also noted. Oral
glucose tolerance is impaired in 50%, while frank diabetes mellitus is seen in 10% of
acromegalics. These metabolic changes are however reversible [111].
Colonic malignancies are also documented in patients with GH adenomas
[112–114].
Risk factors for colonic malignancies in Acromegaly
1.Age > 50 years
2.Family history of colonic malignancy
3.>3 skin tags
4.Prior colonic polyps
Reproductive abnormalities have also been observed in patients with GH
adenomas. These include menstrual disturbances and galactorrhea in women and
decreased libido and impotence in men. These effects are due to hyper
prolactinemia with mammosomatotrophs or mixed tumors, stalk effect or decrease
FSH, LH secretion.
11.3 Endocrine diagnostic criteria
Serum IGF-1 is the initial screening method of choice. The diagnosis is con-
firmed by the unsuppressed nadir of GH >1 ng/ml and GH > 0.4 ng/ml following
75 gms of OGTT with documented hyperglycemia.
11.4 Criteria for cure
The criteria for cure in GH adenomas are-
1.GH < 1 ng/ml
2.OGTT and GH <0.4 ng/ml done at 12 weeks post-surgery
3.Normalization of somatomedin -C levels
Transsphenoidal surgery is recommended as primary therapy. Experienced
pituitary neurosurgeons can achieve the therapeutic goals in 80–90% of patients
with microadenomas and 40–60% of those with macroadenomas. The 5-year
recurrence rate is approximately 2–8%. Repeat IGF-1 levels and growth hormone
levels during an oral glucose tolerance test should be obtained about 12 weeks




of therapy is to normalize the serum IGF 1 level and reduce the GH levels
<1.0 ug/L [115].
Medical management is recommended for patients with persistent disease
following surgery. Medical therapy (Table 4) may be considered as first line in
patients who cannot be cured by surgery, has extensive cavernous sinus invasion,
does not have chiasmal compression, or is a poor surgical candidate. If medical
therapy is unavailable, unsuccessful, or not tolerated, stereotactic radiotherapy
(SRT)/Gamma-knife radiosurgery should be considered unless the technique is not
available, there is significant residual tumour burden, or the tumour is too close to
the optic chiasm. The response to radiation therapy takes an average of 3.17 years
and in the meantime the therapy needs to be bridged with medical management.
Remission rates of approximately 60% are observed at 10 years [116].
There is an overall 72% increase in mortality and decrease in 10 years of average
life expectancy in patients with acromegaly. Cardiovascular causes are the leading
cause accounting for about 25%, while cerebrovascular, malignancies and respira-
tory diseases are responsible for 15% each. Mortality is 2.4 times higher in females
while it is 4.8 times more in males.
Factors associated with increased mortality
1.Older age at diagnosis
2.Male gender
3.Increased disease duration
4.High GH levels [>2.5 ng/ml]
5.Elevated IGF-1 levels
6.Active disease
Drug Dose Indication Side effects
Cabergoline 0.5–2 mg/
week
modest elevations of serum IGF-1 and









significant disease (ie, with moderate-
to-severe signs and symptoms of GH
excess and without local mass effects)
Abdominal cramps, flatulence,






significant disease Abdominal cramps, flatulence,






significant disease Abdominal cramps, flatulence,





significant disease Hepatotoxicity, nausea,
diarrhea
LAR – Long-acting release
Table 4.





9.Need for radiotherapy for disease control
12. Corticotroph adenoma and Cushing’s disease
Of all the pituitary adenomas, the corticotroph adenomas are the most difficult
ones to diagnose and treat. The diagnosis revolves between Cushing’s syndrome and
disease wherein the first one is of non-specific etiology and is produced by any
cause of glucocorticoid excess while the latter is due to a pituitary adenoma secret-
ing excess ACTH and thus hypercortisolemia. Cushing’s disease is seen in up to
10–16% of all surgically resected pituitary adenomas.
Females are more commonly affected than male, with a M:F ration ranging
between 1:3 to 1:10. Though can be seen at any age, is commonly found in 3rd and
5th decade [117].
12.1 Pathology
Corticotroph adenoma (CA) are derived from TPIT-lineage adenohypophysial
cells that express ACTH and proopiomelanocortin-derived peptides. These tumors
are subdivided into densely granulated CA, sparsely granulated CA and Crooke cell
adenoma (CCA) based on secretary granules and cytokeratin accumulation.
More than 80% of the tumors are microadenomas and the rest are
macroadenomas. DGCA is the most common subtype in patients presented with
Cushing disease. The staining pattern of ACTH granules in SGCA and DGCA are
parallel to staining pattern of GH in pure somatotroph adenoma. SGCA are less
frequent than DGCA and usually presented as macroadenoma. CCA are rare sub-
types, in which cells have typical Crooke hyaline change. These cells are composed
of dense perinuclear deposition of cytokeratin filaments appearing as thick hyaline
ring. As a result of this rearrangement of cellular organelles and secretary granules
to the periphery noted.
12.2 Clinical features
These adenomas are usually microadenomas and seldom cause symptoms of
mass effect on the parasellar structures. The main clinical features are due to the
hypercortisolemia [118, 119].
1.There is abnormal centripetal fat deposition leading to truncal obesity. The
accumulation of fat in the face gives rise to characteristic “moon facies”, while
the deposition in the supraclavicular area and cervicodorsal region gives rise to
“buffalo-hump” appearance.
2.There is thinning of the skin due to atrophy of epidermis and connective
tissue. Increased capillary fragility leads to easy bruising and a plethoric face.
Purple striae due to stretching of the skin are noted on the abdomen and
flanks. Hyperpigmentation and hirsutism are also observed.
3.A multitude of metabolic disturbances are observed in these patients.




demineralization leading to osteoporosis especially in the vertebral bodies is
frequent. Hypocalacemic tetany have also been described. Hypokalemic
alkalosis due to mineralocorticoid effect of cortisol on the renal tubules [120].
4.The effects of hypercortisolemia lead to suppression of TSH leading to features
of hypothyroidism. Suppression of gonadotropic releasing hormone leads to
menstrual disturbances in females, impotence in males and decreased libido in
either gender [121–123].
5. Impaired host defences due to hypercortisolaemic effects on the immune system
leads to repeated infections ranging from superficial skin infections like tinea
versicolor or oral candidiasis to severe life-threatening sepsis [124–126].
6.Psychiatric disturbances range from depression, emotional liability to frank
psychosis. Structural changes and cognitive effects have also been observed
[127–131].
The case fatality rate in Cushing’s disease reaches up to 50% at 5 years, with
cardiovascular events leading the cause followed by infections and suicide
[118, 132].
12.3 Endocrine evaluation
The first step in a suspected case of Cushing’s disease is establishment of the fact
that there is a state of hypercortisolaemia and that pituitary adenoma is the cause of
it before jumping upon radiological investigations as incidentalomas occur in 10%
of cases. Further a detailed evaluation of the medications used to rule out exogenous
use of steroids is required.
The biochemical evaluation is to rule out exogenous steroid use by ordering a
basal serum cortisol [10].
Step1: Establish hypercortisolaemic state: [133].
a. 24 hours urinary cortisol – this is a simple and sensitive screening measure.
This is based on the fact that urinary free cortisol raises exponentially for
quantum increases in plasma cortisol. With sensitivity (53–97%) and
specificity (86–91%), this is highly useful in patients with high cortisol
binding globulins.
b. Elevation of basal plasma cortisol at 11 pm
c. Salivary cortisol measurements at 11 pm is another method to detect cortisol
excess and alterations in diurnal variations which are the earliest and subtle
biochemical changes, with sensitivity and specificity of 92 and 100%,
respectively.
d. Low Dose Dexamethasone test: This is based on the principle of suppression
of hypothalamic-pitutitary axis and this decrease in ACTH and morning
cortisol levels to <5 micogms/dl by dexamethasone. This was conventionally
done by giving 0.5 mgs every 6th hourly for 48 hours before 8 am serum
cortisol. This has been replaced by single 11 pm dose of 1 mg of
dexamethasone and 8 am serum cortisol measurement.
Step 2: Determine if the cortisol excess is ACTH dependent or independent.
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ACTH levels are low (<10 pg./ml) if there is autonomous production by the
adrenal gland and the levels are elevated (>20 pg./ml) if a pituitary tumor or
ectopic ACTH or corticotropin releasing hormone production is the cause. The level
of elevations also give a clue to the cause with moderate elevations of 80–200 pgm/
ml seen in corticotroph adenomas while values >200 pg./ml are seen in ectopic
ACTH lesions.
Step 3: Distinguishing Cushing’s disease from ectopic ACTH states.
The secretory activity of corticotroph adenoma, unlike ectopic ACTH is not
autonomous and retains negative feedback responsiveness to glucocorticoid, at
higher thresholds. This is the basis of high dose dexamethasone test.
2mgs of dexamethasone is given every 6th hourly for 48 hours and the urinary
cortisol is measured. A 50% reduction in urinary cortisol secretion is appropriate
suppression and is suggestive of pituitary adenoma. Otherwise, 8–32 mgs of single
dose dexamethasone is given at 11 pm and serum cortisol is measured at 8 am. A
50% reduction is suggestive of suppressive response. This has a sensitivity, speci-
ficity and diagnostic accuracy of 89%, 100% and 91%, respectively [134].
CRH stimulation test:
The corticotroph adenomas have CRH receptors and hence the levels of ACTH
increase following intravenous CRH. A positive response of increase in 50% in
plasma ACTH or 20% raise in plasma cortisol is observed in corticotrophs adeno-
mas. Negative results are seen in ectopic ACTH producing lesions as the pituitary
corticotrophs are chronically suppressed and are resistant to stimulatory effects of
CRH. Diagnostic accuracy of this test is approximately 98% [135, 136].
In some cases, to differentiate between a pituitary vs. an ectopic source of
ACTH, inferior petrosal sinus sampling is done, in which catheters are threaded up
to the petrosal sinuses that drain the pituitary venous system. ACTH levels are
measured from each petrosal sinus and peripherally before and after stimulation
with corticotropin-releasing hormone. The basal central to peripheral ACTH >2 is
suggestive of corticotroph adenoma while a ratio < 1.7 is suggestive of ectopic
ACTH lesion. Following CRH stimulation, a ratio of >3 is diagnostic of corticotroph
adenoma with sensitivity and specificity of 96–100%.
The ACTH concentration that exceeds the other side by 1.5 times is likely to be
the side of adenoma with sensitivity, specificity and diagnostic accuracy for
laterality is 96%, 100% and 78%, respectively [135–138].
12.4 Radiology
As 80–90% of corticotroph adenomas are microadenomas, dynamic contrast
MRI of the pitutitary is needed with sensitivity and specificity of 60 and 87%,
respectively. Volume interpolated 3D spoiled gradient echo (VI-SGE) helps in
detection of microadenoma with a sensitivity and specificity of 87% and 100%,
respectively [139–143].
Trans sphenoidal surgery is the initial treatment for an ACTH secreting pituitary
adenoma. The remission rates with surgery are 52–96%. The positive predictors for
remission following surgery are- 1. Visualisation of adenoma on imaging, 2. Size and
extent of adenoma, with microadenomas and without invasion into cavernous sinus
faring better and 3. Histopathological confirmation of adenoma. The recurrence
rates vary from 15 to 66%. Radiotherapy is the second line of management for
persistent or recurrent disease with conventional radiotherapy faring better than
stereotactic radiosurgery.
In case of no cure after surgery, or radiotherapy/ stereotactic radiosurgery,




13. TSH secreting adenoma
Thyrotroph adenoma (TA) arise from PIT-1 lineage adenohypophyseal cells
with chief expression of Thyroid stimulating hormone.
(TSH). These tumors are most infrequent tumors, accounting for less than 2% of
all pituitary adenomatous tumors. Excessive secretion of TSH makes thyroid to
make excess production of T3 and T4 resulting in hyperthyroidism. An occasional
case of TA associated with primary hypothyroidism are reported. The tumor
derived from thyroid deficiency are distinct from classical TA clinically, routine
microscopy and ultra-structurally.
Patients should be rendered euthyroid with antithyroid drugs like methimazole,
propylthiouracil before undertaking transsphenoidal surgery. Patients not cured by
surgery can be treated with somatostatin analogues (Octreotide LAR and
Lanreotide depot) and by irradiation.
14. Gonadotroph adenoma
Gonadotroph adenoma (GA) are most common pituitary adenoma arise from
SF-1 lineage adenohypophysial cell with production of FSH and or LH. These
tumors account for highest percentage as clinically non-functioning adenomas. GA
are usually macroadenomas with often infiltration into suprasellar and parasellar
compartments. Incidental detection of these tumors is increasing these days due to
widespread use of CT and MRI. There is a male predominance among middle age
and older people. These tumors show a prominent pseudo-rosette pattern around
blood vessels mimicking a close diagnosis of esthesioneuroblastoma. Usage of SF-1
immunohistochemistry helps in differentiating these two.
15. Plurihormonal adenoma
Plurihormonal adenomas are also rare adenohypophysial tumours with two or
more hormone expressions. They account for 0.9% of all pituitary adenomas.
They are morphologically monomorphous with single type of tumours cells, but
functionally mixture of different hormone families. There are two subtypes of
plurihormonal adenomas, PIT-1 positive adenoma (previously called subtype 3
adenoma) and Adenoma with unusual immunohistochemical combination. Most
common of these are Plurihormonal PIT-1 positive adenomas with unusual combi-
nation of GH, PRL and TSH. Adenomas with combination of GH and PRL or FSH
and LH are not considered as plurihormonal. Adenoma with unusual immunohis-
tochemical combination is unrelated to single cell lineage. For example, combina-
tion of GH or PRL with ACTH.
Double adenoma is different from plurihormonal adenomas, existence of two
distinct tumor masses in same gland, representing a collision tumor. They tumours
are usually incidental tumours, whereas plurihormonal adenomas are
macroadenomas.
Silent adenoma presents clinically as non-functioning adenomas, but the surgical
resected samples are immunopositive for hormonal factors and their corresponding
transcriptional factors. They account for approximately 30% of all pituitary adeno-
mas. To present clinically early, they lack hormonal function. At the time of pre-
sentation, several cases tend to exhibit signs of mass effects and few cases with
hypothyroidism due to stalk compression or tissue destruction. The diagnosis of
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Drug Mechanism of action Dosage Adverse effects
Ketoconazole Inhibits the side-chain cleavage
complex
(steroidogenic acute regulatory
protein [StAR] and 20,22-desmolase
[CYP11A1]), CYP11B1 and
17α hydroxylase/17,20-lyase







Etomidate Blocks multiple steps of
steroidogenesis,






[>0.1 mg/kg/h], which will
cause apnea and
somnolence)






Mitotane a. Adrenolytic action caused by lipid
accumulation and atrophy of the
fascicularis and reticularis regions
of the adrenal cortex
b. inhibition of steroidogenesis
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silent adenoma is exclusively based on immunohistochemical markers against tran-
scriptional factors and hormones expressed. The morphology of these tumors cor-
responds to those of their functioning counterparts. The characterization of silent
adenoma is important as they determine prognosis. For e.g.: Silent Corticotroph
adenoma is associated with aggressive behavior of early recurrence rate when
compared to other silent tumors.
Atypical adenoma is defined as tumor cells with extensive nuclear staining for
p53, high mitotic index and Ki-67 proliferative index >3%. The prognostic activity
related to proliferation of pituitary tumors are extensively studied in the last two
decades. But, the significance of proliferation markers or correlation with tumor
invasiveness and recurrence could not be established using above classification.
Ki67 labelling is not predictive factor for recurrence risk, but could be a useful
predictor of progression risk in tumor remnants. Hence, in new classification the
term atypical adenomas are no longer used. The best prognosticator still remains the
tumor invasiveness hormone produced and subtype of particular adenoma.
16. Follow up of patients with pituitary adenoma
The frequency of testing and the criteria for remission/cure for patients under-
going treatment for pituitary adenoma are elaborated in the Table 6 [144].
17. Pituitary apoplexy
Pituitary apoplexy, is a clinical syndrome with incidence ranging from 4 to 20%,
due to varying defining clinical criteria and presentation, ranging from subclinical
to life threatening situation. It is a serious yet rare condition affecting the patients
with pituitary lesions. Apoplexy is referred to as acute infarction of pituitary gland
with or without haemorrhage. Usually, patients present due to sudden haemorrhage
in adenoma and less often with bleed within infarcts or in the cystic lesions like
Rathke’s cyst. The rapid expansion of sellar contents manifests classically as head-
ache, visual disturbances, and varying features of hypopituitarism [145, 146].
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serum GH <0.14 ug/L suggests “surgical remission,”
serum GH <1 ug/L indicates “control







Serum prolactin every 3 months for the first year
after completion of therapy and annually thereafter









Undetectable TSH and positive T3 suppression test
with undetectable TSH and no response to TRH (or
central hypothyroidism)
Table 6.




Varying pathophysiological mechanisms have been postulated for the occur-
rence of pituitary apoplexy- (1) rapid growth of the tumour outgrowing the vascu-
lar supply, (2) compression of the superior hypophyseal trunk along the stalk, (3)
intrinsic vasculopathy with incomplete maturation of the basal membrane and (4)
overexpressed VEGF leading to risk of haemorrhage.
17.2 Precipitating factors
Though most often pituitary apoplexy occurs without any external precipitating
events, few events like a head injury, coughing/sneezing, idiopathic thrombocyto-
penic purpura, spinal anaesthesia, radiotherapy, pregnancy have been implicated.
Medications like anti-platelet drugs, anti-coagulants, clomiphene, leuprolide,
goserlin and oestrogen have been implicated. Bromocriptine and cabergoline
administered for prolactinomas have also been reported to have precipitated pitui-
tary apoplexy.
17.3 Grading of pituitary apoplexy
The first grading of pituitary apoplexy was suggested by Rajashekaran et al., in
their seminal work of guidelines suggested a scoring system from 0 to 10, which
included level of consciousness (0–4), visual acuity (0–2), visual field defects (0–2)
and ocular palsies (0–2). They proposed such objective scoring system to monitor
conservatively managed patients and assess the effect of surgical intervention, with
a long-term aim of a randomised control trial for validation of management. [147]
Giritharan et al. (2016) applied this scoring system retrospectively to their database
of cases with apoplexy and observed that lower PAS grades could be managed
conservatively while higher grades required immediate surgical intervention [148].
Jho et al. (2014) [149] proposed a severity grading system based on clinical and
imaging features into a 5-grades: (1) Grade 1- asymptomatic (subclinical); (2)
Grade 2- only endocrine symptoms; (3) Grade 3- presence of headache; (4) Grade
4- ocular palsies; (5) Grade 5- Visual deficits or altered consciousness not allowing
testing for visual deficits. They had further 3 clinical subgroups or modifiers (p, r, s)
wherein the presence of prolactinoma(p), Rathke’s cyst (r) with haemorrhage and
co-morbidities/sick (s) were preferentially managed medically. They reviewed their
database of over 20 years and proposed algorthimic based treatment with immedi-
ate surgery for higher grades and conservative/medical management for lower
grades.
17.4 Imaging in pituitary apoplexy
MRI of the brain is the current modality of choice for pituitary apoplexy. MRI is
much superior to CT in the diagnosis of pituitary apoplexy with a sensitivity rang-
ing from 88–90% [145, 150]. The signal intensity changes depend upon the changes
in the haemoglobin or in turn the age of the bleed.
Fluid–fluid level sign can be seen in old bleeds with supernatant T1W
hyperintense upper/anterior fluid level corresponds to extracellular met Hb,
while the lower/posterior iso to hypo intense area is related to sedimented blood
products [151].
Thickening of mucosa in pituitary apoplexy was demonstrated by Arita et al.
[150] in 9 of their 11 patients at 7 days, which was predominantly in the compart-




Histopathological examination of the mucosa in those who underwent trans-
sphenoidal resection swollen subepithelial layer of mucosa. In others, a repeat MRI
showed complete resolution without any treatment. Mucosal thickening does not
preclude a transsphenoidal surgical approach.
Sheehan syndrome refers to postpartum apoplexy and usually occurs in women
having suffered postpartum hemorrhage and hypovolemia. It is hypothesized that
hypertrophied pituitary gland is more susceptible to infarction from hypovolemia.
18. Recurrent pituitary apoplexy
Recurrent pituitary apoplexy, is a rare event described by several authors as few
case reports. The prominent one is by Houseman et al. (2019) wherein they retro-
spectively analysed their data of 798 surgically treated patients over a period of
27 years and found that apoplexy was noted in 76 patients. There were only 4
patients (5.3%) who had recurrent episodes of apoplexy. These haemorrhagic
recurrences were noticed when the Knosp’s score was more than 4, implying com-
plete encasement of ICA and hence incomplete tumor resection (8%) in the cav-
ernous sinus (23.5%). Brown et al. (2020) described a single case of multiple
episodes of pituitary apoplexy over 11 years, which interestingly has varying phe-
notypes changing from silent gonadotropic to silent corticotroph adenoma. The
MIB-1 index was however, consistently high at 10%. Teasdale et al. (2015)
described recurrent pituitary apoplexy following development of a neoplasm adja-
cent to the sella. Tumour residue or recurrence are the major factors responsible for
recurrent pituitary apoplexy and need a close follow-up. The management is similar
to any other pituitary apoplexy which includes stabilisation of general and hor-
monal status. Surgical decompression of the hematoma and the residual tumour is
the treatment of choice, followed closely by hormone replacements. Follow-up
imaging to look for residual/recurrent tumour and radiotherapy. A further look into
the molecular markers predisposing to recurrent haemorrhages to be looked in
future [152–160].
19. Conclusion
• Pituitary neoplasms are common intracranial tumours accounting for approx.
15% of all intracranial tumours.
• The pituitary neoplasms are believed to originate due to aberration in the
normal growth and differentiation of pituitary stem cells. The detection of the
pituitary specific transcription is now the basis of the recent most WHO
classification.
• The clinicalmanifestations of such tumours are due to- hormone excess, deficiency
of other pituitary hormones, pressure effects onoptic pathways, surroundingbrain
parenchyma, ventricular system, paranasal sinuses and systemic.
• The diagnosis andmanagement require a close collaboration between
endocrinologist, radiologist, neurosurgeon, pathologist and radiation oncologist.
• The goals of therapy include- hormonal remission, decompression of neural
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